All In Biotech

Drug Trial Radar · NCT02607930

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Last checked: Nov 19, 2026Latest source record: Mar 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 631 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

631

Actual

Start

Nov 13, 2015

Primary completion

May 9, 2017

Study completion Jul 2, 2021

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Nov 18, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of a fixed dose combination (FDC) containing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus a FDC containing abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) in HIV-1 infected, antiretroviral treatment naive-adults.

Conditions

  • HIV-1 Infection

Interventions

  • ABC/DTG/3TCDrug

    600/50/300 milligrams (mg) tablets administered orally, once daily

  • B/F/TAFDrug

    50/200/25 mg tablets administered orally, once daily, without regard to food

  • ABC/DTG/3TC PlaceboDrug

    Tablets administered orally, once daily

  • B/F/TAF PlaceboDrug

    Tablets administered orally, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot AlgorithmTime frame: Week 48

Locations

121 sites in 10 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Spectrum Medical Group

    Phoenix, Arizona

  • Pueblo Family Physicians

    Phoenix, Arizona

  • Kaiser Permanente Medical Center

    Los Angeles, California

  • Ruane Clinical Research Group, Inc.

    Los Angeles, California

  • Anthony Martin Mills MD A Medical Corporation, DBA Mills Clinical Research

    Los Angeles, California

  • Alameda Health System- Highland Hospital

    Oakland, California

  • University of California Davis

    Sacramento, California

  • Kaiser Permanente Medical Group

    Sacramento, California

  • La Playa Medical Group

    San Diego, California

  • Kaiser Permanente

    San Francisco, California

  • Kaiser Permanente

    San Leandro, California

  • The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Center

    Torrance, California

  • Apex Research

    Denver, Colorado

  • Whitman-Walker Institute

    Washington D.C., District of Columbia

  • Providence Hospital - DC

    Washington D.C., District of Columbia

  • Capital Medical Associates

    Washington D.C., District of Columbia

  • Medical Faculty Associates

    Washington D.C., District of Columbia

  • Therafirst Medical Center

    Fort Lauderdale, Florida

  • Gary J. Richmond, M.D., P.A.

    Fort Lauderdale, Florida

  • Midway Immunology and Research Center

    Ft. Pierce, Florida

  • AHF Kinder Medical Group

    Miami, Florida

  • Site not named

    Miami, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • AIDS Healthcare Foundation-Miami Beach

    Pensacola, Florida

  • St. Joseph's Comprehensive Research Institute

    Tampa, Florida

  • AIDS Research and Treatment Center of the Treasure Coast

    Vero Beach, Florida

  • Triple O Research Institute PA

    West Palm Beach, Florida

  • Emory University

    Atlanta, Georgia

  • Atlanta Infectious Disease Group PC

    Atlanta, Georgia

  • Aids Research Consortium of Atlanta Inc

    Atlanta, Georgia

  • Augusta University

    Augusta, Georgia

  • Infectious Disease Specialists of Atlanta

    Decatur, Georgia

  • Chatham County Health Department

    Savannah, Georgia

  • Indiana CTSI Clinical Research Center

    Indianapolis, Indiana

  • Louisiana State University Health Sciences Center

    New Orleans, Louisiana

  • Baystate Medical Center

    Springfield, Massachusetts

  • Be Well Medical Center

    Berkley, Michigan

  • Henry Ford Health System

    Detroit, Michigan

  • Hennepin County Medical Center

    Minneapolis, Minnesota

Showing 40 of 121 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.